What is Biocorrx Inc's earnings per share (EPS)?

Biocorrx Inc (BICX) reported diluted earnings per share of $-0.19 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biocorrx Inc Financials

BICX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Biocorrx Inc (BICX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

Biocorrx Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.67x

For every $1 of reported earnings, Biocorrx Inc generates $0.67 in operating cash flow (-$2.3M OCF vs -$3.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$797K

YoY+10301.1%

5Y CAGR+45.4%

10Y CAGR-1.5%

Biocorrx Inc generated $797K in revenue in fiscal year 2025. This represents an increase of 10301.1% from the prior year.

EBITDA

-$4.8M

YoY+5.9%

Biocorrx Inc's EBITDA was -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.9% from the prior year.

Net Income

-$3.4M

YoY+34.0%

Biocorrx Inc reported -$3.4M in net income in fiscal year 2025. This represents an increase of 34.0% from the prior year.

EPS (Diluted)

$-0.19

Biocorrx Inc earned $-0.19 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$139K

YoY+58.3%

5Y CAGR-25.1%

10Y CAGR-4.5%

Biocorrx Inc held $139K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

26M

YoY+98.5%

5Y CAGR+37.0%

Biocorrx Inc had 26M shares outstanding in fiscal year 2025. This represents an increase of 98.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-606.0%

YoY+66223.8pp

5Y CAGR+5503.8pp

10Y CAGR-52.6pp

Biocorrx Inc's operating margin was -606.0% in fiscal year 2025, reflecting core business profitability. This is up 66223.8 percentage points from the prior year.

Net Margin

-431.5%

YoY+67567.2pp

5Y CAGR+2428.1pp

10Y CAGR+73.1pp

Biocorrx Inc's net profit margin was -431.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 67567.2 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.8M

YoY+19.3%

5Y CAGR-16.2%

Biocorrx Inc invested $1.8M in research and development in fiscal year 2025. This represents an increase of 19.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BICX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$797K+10301.1%	$8K-91.4%	$89K-58.3%	$214K+343.0%	$48K-60.6%	$123K
Cost of Revenue	N/A	$2K-95.4%	$36K+89.9%	$19K+222.2%	$6K-93.9%	$96K
Gross Profit	N/A	$6K-88.7%	$53K-72.7%	$195K+359.8%	$42K+58.9%	$27K
R&D Expenses	$1.8M+19.3%	$1.5M+66.4%	$891K-38.9%	$1.5M-9.1%	$1.6M-62.4%	$4.3M
SG&A Expenses	$3.8M+5.0%	$3.6M+25.6%	$2.9M-15.7%	$3.4M-8.9%	$3.7M+18.1%	$3.2M
Operating Income	-$4.8M+5.7%	-$5.1M-35.2%	-$3.8M+19.4%	-$4.7M+14.7%	-$5.5M+26.5%	-$7.5M
Interest Expense	$0-100.0%	$777K+300.3%	$194K+28.5%	$151K+677.2%	$19K-96.2%	$511K
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$3.4M+34.0%	-$5.2M-38.2%	-$3.8M+13.9%	-$4.4M+16.0%	-$5.2M-48.6%	-$3.5M
EPS (Diluted)	$-0.19	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$635K+256.4%	$178K+32.1%	$135K	N/A	$0-100.0%	$4K+11.7%	$4K-80.9%	$19K
Cost of Revenue	N/A	N/A	$0	N/A	$0	$0-100.0%	$2K-87.2%	$13K
Gross Profit	N/A	N/A	$135K	N/A	$0-100.0%	$4K+107.1%	$2K-66.8%	$6K
R&D Expenses	$1.0M+238.4%	$297K+83.3%	$162K	N/A	$460K-14.2%	$536K+150.8%	$214K+66.7%	$128K
SG&A Expenses	$1.1M-6.4%	$1.2M+38.1%	$886K	N/A	$1.2M+43.7%	$830K+10.7%	$750K+8.1%	$694K
Operating Income	-$1.9M-37.6%	-$1.4M-50.7%	-$938K	N/A	-$1.7M-21.2%	-$1.4M-41.4%	-$969K-17.7%	-$823K
Interest Expense	$30K-19.1%	$37K-58.1%	$87K	N/A	$149K-53.1%	$318K+74.8%	$182K+75.5%	$104K
Income Tax	N/A	$0	$0	N/A	$0	$0	$0	$0
Net Income	-$1.9M-55.5%	-$1.2M-46.6%	-$841K	N/A	-$1.5M-22.2%	-$1.2M+1.6%	-$1.2M-27.6%	-$969K
EPS (Diluted)	$-0.11-57.1%	$-0.07	N/A	N/A	$-0.14-7.7%	$-0.13	N/A	N/A

BICX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.1M+456.4%	$386K-0.8%	$389K-49.3%	$767K-6.5%	$820K-55.1%	$1.8M
Current Assets	$814K+590.3%	$118K-36.9%	$187K-41.0%	$317K+38.8%	$228K-76.6%	$975K
Cash & Equivalents	$139K+58.3%	$88K+35.0%	$65K-4.9%	$69K-20.1%	$86K-85.5%	$592K
Inventory	$143K	$0	N/A	N/A	N/A	N/A
Accounts Receivable	$253K	$0-100.0%	$740-97.9%	$35K+2258.5%	$2K+200.0%	$500
Goodwill	$563K	$0	N/A	N/A	N/A	N/A
Total Liabilities	$13.7M+9.3%	$12.5M+22.5%	$10.2M+13.9%	$9.0M+15.3%	$7.8M+28.9%	$6.0M
Current Liabilities	$8.3M+1.2%	$8.2M+27.6%	$6.4M+19.9%	$5.4M+22.3%	$4.4M+43.7%	$3.1M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$100K	N/A
Total Equity	-$11.2M+7.4%	-$12.1M-23.4%	-$9.8M-21.6%	-$8.1M-16.0%	-$7.0M-65.3%	-$4.2M
Retained Earnings	-$86.6M-4.1%	-$83.2M-6.5%	-$78.1M-5.1%	-$74.3M-6.2%	-$70.0M-8.2%	-$64.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7.5M+12.8%	$6.7M-1.8%	$6.8M+1662.2%	$386K-40.0%	$644K+34.5%	$479K+50.7%	$317K-18.4%	$389K
Current Assets	$1.5M+177.2%	$527K-6.8%	$566K+379.5%	$118K-66.6%	$353K+105.3%	$172K+13.5%	$152K-19.0%	$187K
Cash & Equivalents	$288K+157.2%	$112K+363.4%	$24K-72.6%	$88K+97714.4%	$90-98.9%	$8K-91.7%	$101K+55.0%	$65K
Inventory	$155K+16.3%	$134K0.0%	$134K	$0	N/A	N/A	N/A	N/A
Accounts Receivable	$194K+279.5%	$51K-54.2%	$112K	$0	$0	$0	$0-100.0%	$740
Goodwill	$2.8M0.0%	$2.8M0.0%	$2.8M	$0	N/A	N/A	N/A	N/A
Total Liabilities	$20.3M+3.1%	$19.7M+5.9%	$18.6M+48.7%	$12.5M+0.3%	$12.5M+8.7%	$11.5M+3.8%	$11.1M+8.3%	$10.2M
Current Liabilities	$15.0M+3.3%	$14.6M+8.3%	$13.4M+63.8%	$8.2M-0.2%	$8.2M+12.4%	$7.3M+2.0%	$7.2M+11.5%	$6.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$13.5M-6.8%	-$12.6M-9.2%	-$11.6M+4.7%	-$12.1M-2.4%	-$11.8M-7.5%	-$11.0M-2.4%	-$10.7M-9.3%	-$9.8M
Retained Earnings	-$87.2M-2.2%	-$85.3M-1.5%	-$84.1M-1.0%	-$83.2M-1.4%	-$82.0M-1.8%	-$80.6M-1.5%	-$79.3M-1.6%	-$78.1M

BICX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.3M-109.6%	-$1.1M+40.8%	-$1.9M+9.2%	-$2.0M+42.3%	-$3.5M-64.4%	-$2.2M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$2K	$0
Free Cash Flow	N/A	N/A	N/A	-$2.0M+42.3%	-$3.5M-64.5%	-$2.2M
Investing Cash Flow	N/A	N/A	N/A	$0+100.0%	-$50K-441.9%	-$9K
Financing Cash Flow	$2.3M+110.0%	$1.1M-39.5%	$1.8M-8.6%	$2.0M-34.3%	$3.1M+2771.8%	$107K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$634K-401.5%	-$126K+81.7%	-$690K-179.0%	-$247K+30.9%	-$358K-135.4%	-$152K+55.3%	-$340K+36.4%	-$534K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$810K+278.2%	$214K-65.8%	$626K+86.7%	$335K-4.1%	$349K+490.4%	$59K-84.2%	$376K-15.2%	$443K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BICX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	78.3%+18.6pp	59.6%-31.5pp	91.1%+3.3pp	87.8%+66.1pp	21.8%
Operating Margin	-606.0%+66223.8pp	-66829.8%-62581.5pp	-4248.3%-2051.3pp	-2197.0%+9217.8pp	-11414.7%-5304.8pp	-6109.9%
Net Margin	-431.5%+67567.2pp	-67998.7%-63769.8pp	-4228.9%-2182.1pp	-2046.8%+8747.6pp	-10794.3%-7934.7pp	-2859.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-160.2%+1190.3pp	-1350.5%-380.9pp	-969.6%-398.6pp	-571.0%+64.5pp	-635.5%-443.5pp	-191.9%
Current Ratio	0.10+0.1	0.01-0.0	0.03-0.0	0.060.0	0.05-0.3	0.32
Debt-to-Equity	-1.22-0.2	-1.030.0	-1.04-1.0	0.00+0.0	-0.01+1.4	-1.43
FCF Margin	N/A	N/A	N/A	-954.8%+6378.0pp	-7332.8%-5577.9pp	-1754.9%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	100.0%	N/A	N/A	100.0%+46.1pp	53.9%+22.9pp	31.1%
Operating Margin	-306.3%+487.0pp	-793.3%-98.0pp	-695.3%	N/A	N/A	-33852.9%-7093.5pp	-26759.4%-22415.2pp	-4344.2%
Net Margin	-301.9%+390.1pp	-692.0%-68.3pp	-623.7%	N/A	N/A	-30095.1%+4070.0pp	-34165.1%-29048.3pp	-5116.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-25.5%-7.0pp	-18.5%-6.1pp	-12.4%	N/A	-231.1%+23.3pp	-254.4%+135.2pp	-389.6%-140.4pp	-249.2%
Current Ratio	0.10+0.1	0.040.0	0.04+0.0	0.01-0.0	0.04+0.0	0.020.0	0.020.0	0.03
Debt-to-Equity	-1.51+0.1	-1.56+0.0	-1.61-0.6	-1.03+0.0	-1.05-0.0	-1.04-0.0	-1.03+0.0	-1.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$11.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Veltex VLXC

$3.9M

Xcelerate Inc XCRT

$4.3M

Aesthetic Medical International Holdings Group Ltd PAIYY

$4.6M

Numinus Wellness Inc. NUMIF

$3.2M

Selectis Health Inc GBCS

$12.6M

Frequently Asked Questions

What is Biocorrx Inc's annual revenue?

Biocorrx Inc (BICX) reported $797K in total revenue for fiscal year 2025. This represents a 10301.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biocorrx Inc's revenue growing?

Biocorrx Inc (BICX) revenue grew by 10301.1% year-over-year, from $8K to $797K in fiscal year 2025.

Is Biocorrx Inc profitable?

No, Biocorrx Inc (BICX) reported a net income of -$3.4M in fiscal year 2025, with a net profit margin of -431.5%.

What is Biocorrx Inc's EBITDA?

Biocorrx Inc (BICX) had EBITDA of -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biocorrx Inc's operating margin?

Biocorrx Inc (BICX) had an operating margin of -606.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Biocorrx Inc's net profit margin?

Biocorrx Inc (BICX) had a net profit margin of -431.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Biocorrx Inc's operating cash flow?

Biocorrx Inc (BICX) generated -$2.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Biocorrx Inc's total assets?

Biocorrx Inc (BICX) had $2.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Biocorrx Inc spend on research and development?

Biocorrx Inc (BICX) invested $1.8M in research and development during fiscal year 2025.

How many shares does Biocorrx Inc have outstanding?

Biocorrx Inc (BICX) had 26M shares outstanding as of fiscal year 2025.

What is Biocorrx Inc's current ratio?

Biocorrx Inc (BICX) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Biocorrx Inc's debt-to-equity ratio?

Biocorrx Inc (BICX) had a debt-to-equity ratio of -1.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biocorrx Inc's return on assets (ROA)?

Biocorrx Inc (BICX) had a return on assets of -160.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Biocorrx Inc's cash runway?

Based on fiscal year 2025 data, Biocorrx Inc (BICX) had $139K in cash against an annual operating cash burn of $2.3M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Biocorrx Inc's debt-to-equity ratio negative or unusual?

Biocorrx Inc (BICX) has negative shareholder equity of -$11.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Biocorrx Inc's Piotroski F-Score?

Biocorrx Inc (BICX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biocorrx Inc's earnings high quality?

Biocorrx Inc (BICX) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.